Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Zeria Aims at 50% Market Share for Asacol: President Ibe
November 30, 2009
- NDA for Liraglutide, Vildagliptin to Be Reviewed
November 30, 2009
- JDS to Include HbA1c in Its Diagnostic Criteria
November 30, 2009
- Nippon Kayaku Licenses Apaziquone from Spectrum
November 23, 2009
- FPMAJ's Proposal Is a Package Deal: Mr Hasegawa
November 23, 2009
- Top-Five Wholesalers'Operating Profits Down 19% Despite 6.6% Increase in Sales
November 23, 2009
- Mr Miura to Represent Pharmacists Because of His Business Experience at Hospital
November 23, 2009
- Banyu to Recommend Januvia in First-Line Therapy
November 23, 2009
- Novartis Applies for New-Type Influenza Vaccine
November 23, 2009
- Plavix Drives Business of sanofi-aventis in Japan: President P. Chocat
November 23, 2009
- Haruo Naito Appointed as President of the IFPMA
November 23, 2009
- Seibule Approved for Combination with Biguanides
November 23, 2009
- PI for Sancuso Completed in Japanese Volunteers: Solasia
November 23, 2009
- Merck's Merger with Schering-Plough Completed
November 23, 2009
- Avastin Approved for NSCLC in Japan: Chugai
November 23, 2009
- Yakult Aims at ¥10 Bil. Sales for Elplat with Stomach Cancer
November 23, 2009
- Sanofi-aventis, Micromet Sign License Agreement for BiTE Antibody
November 23, 2009
- Fludara Obtains Different Additional Indications for Tablet and Injectable
November 23, 2009
- Astellas to Overcome Prograf, Harnal Patent Expiration with New Products: President Nogimori
November 23, 2009
- Daiichi Sankyo Terminates Levofloxacin Patent Litigation
November 23, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…